SCHEMBL6037889

SCHEMBL6037889

O=C1Nc2ccccc2NC1Cc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.58
ALDH1A1 P00352 10/20 0.58
MAPT P10636 4/20 0.58
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
ALOX15 P16050 3/20 0.58
RAB9A P51151 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
HPGD P15428 2/20 0.58
NPC1 O15118 1/20 0.58
TP53 P04637 1/20 0.58
MAPK1 P28482 1/20 0.58
TAAR1 Q96RJ0 1/20 0.56
HDAC8 Q9BY41 2/20 0.54
HSD17B10 Q99714 5/20 0.54
GAA P10253 3/20 0.51
BRPF1 P55201 1/20 0.50
CREBBP Q92793 1/20 0.50
TACR1 P25103 2/20 0.47
GFER P55789 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10326494 1.00 KDM4E (0.58) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL6037887 1.00 KDM4E (0.58) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL17676997 0.87 KDM4E (0.49) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL10327190 0.87 ALDH1A1 (0.49) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL10327014 0.87 KDM4E (0.49) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL10326975 0.87 ALDH1A1 (0.49) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL14933672 0.87 KDM4E (0.52) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL10326670 0.87 KDM4E (0.49) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL17676996 0.87 ALDH1A1 (0.49) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL8871789 0.83 GFER (0.52) KDM4EALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217204-B2 Catalyst for asymmetric hydrogenation TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-07-10 US disclosed
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION TAKASAGO INTERNATIONAL CORPORATION (JP) 2010-12-23 US disclosed
WO-2010140636-A1 ASYMMETRIC HYDROGENATION CATALYST 高砂香料工業株式会社 (JP) 2010-12-09 WO disclosed
US-20060264415-A1 Inhibitors of histone deacetylase METHYLGENE INC. 2006-11-23 US disclosed
EP-1481975-A1 Inhibitors of farnesyl protein transferase BRISTOL-MYERS SQUIBB COMPANY (US) 2004-12-01 EP disclosed
US-6455523-B1 ADMINISTERING 1,4-BENZODIAZEPINE DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT BRISTOL-MYERS SQUIBB COMPANY 2002-09-24 US disclosed
EP-1068190-A1 QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN WARNER-LAMBERT COMPANY LLC (US) 2001-01-17 EP disclosed
US-6011029-A BENZODIAZEPINE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2000-01-04 US disclosed
WO-1999050254-A1 QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN WARNER-LAMBERT COMPANY (US) 1999-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION H1-0, H1-5, ADH5 KDM4E 4195/4885ALDH1A1 223/4885MAPT 2035/4885
US-20060264415-A1 Inhibitors of histone deacetylase HDAC1, HDAC3, HDAC11 KDM4E 67/4885ALDH1A1 781/4885MAPT 3848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.